Hem › Icke-småcellig lungcancer › New York › Rochester
Kliniska studier för Icke-småcellig lungcancer i Rochester, NY
13 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Rochester (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekryterarFas 3
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RekryterarFas 3
- Wilmot Cancer Institute ( Site 0141), Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RekryterarFas 3
- Research Site, Rochester
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekryterarFas 3
- University of Rochester Medical Center, Rochester
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekryterarFas 2/3
- Rochester General Hospital Infectious Disease, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekryterarFas 3
- University of Rochester, Rochester
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RekryterarFriska volontärer välkomna
- University of Rochester, Rochester
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekryterarFas 3
- University of Rochester Medical Center, Rochester
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
RekryterarFas 1
- University of Rochester, Rochester
- University of Rochester, Rochester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekryterarFas 2
- University of Rochester, Rochester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2/3
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster · 10 mi bort
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2
- University of Rochester, Rochester
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
RekryterarFas 2
- University of Rochester, Rochester
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andra studier i Rochester
- Akut myeloid leukemi16 studier
- Lungcancer15 studier
- Bröstcancer15 studier
- Cancer (alla typer)14 studier
- Övervikt14 studier
- Övervikt13 studier
- Prostatacancer10 studier
- Metastaserande cancer8 studier
- Multipelt myelom8 studier
- Blåscancer7 studier
- Myotonisk dystrofi7 studier
- Bukspottkörtelcancer7 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.